• Area: Patras Industrial Zone

• 19,700 sq.m. (co-located with Plant D)

• R&D (surface area): 3,000 sq.m.

The year 2026 marked the establishment of the company’s new Research and Development (R&D) Center, a state-of-the-art facility designed to lead modern scientific advancements. The Center features full infrastructure and advanced equipment, supporting the operations of a modern pharmaceutical facility on both an R&D and a semi-industrial (pilot) scale.

The Center operates with a strong outward-looking approach, actively participating in national and international research programs. Bioequivalence studies are conducted in collaboration with specialized companies, ensuring that the developed generic products meet the strictest criteria for therapeutic equivalence compared to their reference products. Our research activities contribute to the supply of high-quality pharmaceutical products covering a wide range of diseases, with a focus on modern requirements and innovative targeting. The VIANEX Research and Development Center constitutes a strategic investment in innovation, aiming to develop new products and technologies that enhance the company's international competitiveness and create long-term value. Furthermore, it aims to support the sustainability of the healthcare system by providing high-standard generic medicines at a lower cost compared to reference drugs. We bring together talented scientists and through the modern infrastructure of our new facility, we translate ideas into innovative solutions. 

The new Research & Development Center features:

• Storage infrastructure for raw materials, packaging materials, semi-finished and finished products
• Primary packaging areas
• Modern Quality Control department staffed by highly specialized scientific and technological personnel
• Independent loading and unloading zone
• Distinct production areas for a wide range of dosage forms:
  • Non-sterile solid forms (tablets, capsules)
  • Sterile liquid injectables and parenteral solutions
  • Ophthalmic solutions (eye drops)
  • Liquid solutions & suspensions, liquid capsules
  • Semi-solid forms
  • Inhalers and topical sprays

The facility features cutting-edge technologies. The production areas are supported by an advanced HVAC system, ensuring strict operational specifications for cleanrooms. Furthermore, personnel safety and product quality are protected by a central dedusting system that collects generated dust into a central collector, meeting the rigorous safety criteria of pharmaceutical manufacturing. All critical facility parameters are monitored and recorded in real-time through a central building management system (BMS), operating as a unified, intelligent control, regulation and logging center. The company's strategic growth is implemented with absolute respect for the environment, incorporating a model, sustainable design with a low environmental footprint. This commitment is actively demonstrated through the operation of a modern wastewater treatment plant and the utilization of photovoltaic systems for green energy production, proving that business excellence and environmental responsibility coexist harmoniously.